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ABSTRACT 
Proteases Potentiate Fibrocyte Differentiation. (May 2014)  
 
Elkin David Galvis-Carvajal 
Department of Biology  
Texas A&M University  
 
Research Advisor: Dr. Richard Gomer  
Department of Biology  
 
45% of deaths in the United States involve fibrosing diseases and the treatment of non-healing 
chronic wounds costs more than $25 billion annually in the United States alone. Scar tissue 
formation plays a critical role in both wound healing, and fibrosis. Currently, there is not a solid 
understanding of the mechanism that triggers initiation of scar tissue formation in healing 
wounds and fibrosing diseases such as chronic kidney disease, scleroderma, chronic asthma, and 
idiopathic pulmonary fibrosis. Fibrocytes are fibroblast-like cells involved in the formation of 
scar tissue in healing wounds and fibrosing disease. The time required to form scar tissue in a 
wound is related to the amount of fibrocytes present. As fibrocyte differentiation increases, scar 
tissue forms faster; however, if fibrocyte differentiation is hindered, then scar tissue takes longer 
to form.  Thrombin and tryptase are proteases involved in both wound healing and fibrotic 
lesions, while trypsin has been used topically to speed wound healing.  Adding trypsin, thrombin 
and tryptase to PBMC isolated from donor’s blood increases the amount of fibrocyte 
differentiation, suggesting that these proteases play a critical role in the potentiation of fibrocyte 
differentiation.   
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In addition to potentiating fibrocyte differentiation, these proteases also increase the proportion 
of M2a pro-fibrotic macrophages as well as collagen production, both makers for scar tissue 
formation. Fibrocyte differentiation is greatly inhibited by the presence of the plasma protein 
Serum Amyloid P (SAP).  Tryptase and thrombin potentiate fibrocyte differentiation in the 
presence of SAP, suggesting that these proteases can be part of a triggering mechanism for scar 
tissue formation in both healing wounds and fibrotic lesions. Consequently, proteases may be an 
effective treatment for non-healing wounds, and protease inhibitors could be an effective 
treatment for fibrosing diseases.  
.  
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CHAPTER I 
INTRODUCTION 
 
Fibrosing diseases are involved in 45% of the death in the United States [1]. The more than 62 
known fibrosing diseases affect major organs such as the heart, liver and kidneys, as well as 
tissue [1]. Also, other fibroprofliferative fibrosing disorders include scleroderma, keloids, and 
atherosclerosis [1]. Fibrocytes are involved in both wound healing and scar tissue formation, and 
are found in a variety of disease settings such as chronic asthma, idiopathic pulmonary fibrosis, 
nephrogenic systemic pulmonary fibrosis, and scleroderma; therefore, inhibiting fibrocyte 
differentiation in these disorders could be used as a therapeutic.  
 
Chronic wounds affect more than 6.5 million patients and cost $25 billion per year to treat in the 
United States alone. Non-healing chronic wounds predominately affect elderly, obese, and 
diabetic patients [2]. Wound healing is an active process, which involves blood cells, soluble 
intermediates, extracellular matrix, prenchymal cells [3], angiogenesis, and interactions between 
epidermal and dermal cells; these complex interactions are controlled by different cytokines and 
growth factors [4]. Successful wound healing can be divided in three main phases: inflammation, 
proliferation, and remodeling.  During the inflammatory phase neutrophils predominate, which 
allows the wound site to be as clean as possible by removing bacteria and other foreign 
substances found at the wound site. Next, during the proliferation phase fibroblasts play a critical 
role, because they produce extracellular matrix proteins, collagen and fibronectin; thus, 
fibroblasts are fundamental for scar tissue formation. It is during this phase that fibrocytes 
participate in wound healing; monocytes (circulating blood leukocytes) [5], are recruited to 
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injured tissue by different chemokines. Monocytes differentiate into fibrocytes, which are 
fibroblast- like cells that are express CD45+, and secrete collagen, which allows them to form 
scar tissue and contribute to the wound healing process [6]. The rate at which a wound heals is 
related to the amount of fibrocytes present at the wound site; that is, increasing the amount of 
fibrocytes present within a wound potentiates wound healing, while decreasing the amount of 
fibrocytes present within a wound hinders wound healing [2]. The final phase of wound healing 
is remodeling, which is a process that occurs after the wound has closed [4].  
 
Trypsin, tryptase, and thrombin are proteolytic enzymes that have different roles in the body. 
Previous data indicates that proteolytic enzymes can increase the rate at which a wound heals [7]. 
Also, trypsin can speed up wound healing; thus, trypsin has been used in the past in clinical 
application related to wound healing. Trypsin is especially helpful since it can remove any debris 
present at the wound site, decrease edema, and act as an anticoagulant, all these characteristics 
allow trypsin to speed the rate at which a wound heals [8]. Tryptase also plays a role in wound 
healing. Tryptase is secreted by mast cells in wounds and fibrotic lesions and causes fibroblasts 
to proliferate and secrete collagen [9]. Thrombin is directly involved in the wound healing 
process as the main protease of the coagulation cascade. Thrombin plays a role in the formation 
of the fibrous matrix of blood clots; this is accomplished by converting fibrinogen to fibrin. Also, 
thrombin contributes to  platelet formation by triggering shape changes in platelets and releasing 
platelet activating factors [10]. This report shows that proteolytic proteins such as trypsin, 
thrombin and tryptase potentiate fibrocyte differentiation, which offers a feasible solution to the 
problem of wound healing.  
 
5 
 
It has been previously shown that trypsin requires protein supplements (albumin, insulin, and 
transferrin) in order to potentiate fibrocyte differentiation [2]. This suggests that trypsin acts on 
protein supplements, or that protein supplements are necessary in order for trypsin to potentiate 
fibrocyte differentiation [2]. We tested the ability of trypsin, thrombin, and tryptase to potentiate 
fibrocyte differentiation on different supplement-containing media.  
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CHAPTER II 
METHODS 
 
PBMC isolation and culture 
Human blood was collected from adult volunteers after giving written consent and with specific 
approval from the Texas A&M University human subjects Institutional Review Board. 
Peripheral blood mononuclear cells (PBMC) were isolated and cultured as previously described 
[12,3]. Protein-free media (PFM) was Fibrolife basal media (Lifeline Cell Technology, 
Walkersville, MD) supplemented with 10 mM HEPES (Sigma, St. Louis, MO), 1× non-essential 
amino acids (Sigma), 2 mM glutamine (Lonza, Basel, Switzerland), 1 mM sodium pyruvate 
(Sigma), 100 U/ml penicillin and 100 μg/ml streptomycin (Lonza). Serum-free media (SFM) was 
PFM containing 10 μg/ml recombinant human insulin (Sigma), 5 μg/ml recombinant human 
transferrin (Sigma), and 550 μg/ml filter sterilized human albumin (purified as previously 
described [2]), casein from bovine milk (Sigma), ovalbumin from egg white (Acros Organics, 
Waltham, MA), skim milk powder (EMD Millipore), bovine skin gelatin (Sigma), or fish skin 
gelatin (Sigma). For casein the pH was raised to 9, to get the 5 mg/ml protein into solution. The 
pH was brought back to 8 prior to addition to PBMC. Supplements were checked for 
concentration using absorbance at 280 nm. SFM made with each supplement at 500 ug/ml was 
mixed with trypsin at 500 ng/ml for 24 hours at 37˚C and assayed on 4-20% SDS gels (Bio-Rad, 
Hercules, California), which were silver stained to check for purity and protein digestion. Where 
indicated, PFM was supplemented to 2.5% (v/v) with sterile filtered non-blood type specific 
human serum, tested negative for hepatitis A and B and HIV I and II (Lonza and Gemini Bio-
products, West Sacramento, California). 
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Exposure of PBMC to protease  
TPCK-treated bovine trypsin (Sigma) and bovine thrombin (Sigma) were resuspended following 
the manufacturer’s instructions. Tryptase purified from human mast cells (Fitzgerald) was mixed 
with 15 kDa heparin from porcine stomach (Sigma) in a 1:10 molar ratio of tryptase to heparin 
immediately after thawing [11]. Trypsin, thrombin, and tryptase were added to PBMC in a 96-
well plate (BD biosciences) at the indicated concentrations.  
 
Exposure of PBMC to SAP 
Human SAP was purified as previously described [12], with the following modifications. Human 
serum from blood donors was mixed 1:1 with PBS. This serum was mixed with gentle rolling in 
a 10:1 ratio with SP sepharose beads (GE Healthcare, Piscataway, NJ) in 20 mM Tris, 140 mM 
NaCl, 2 mM CaCl2 pH 8.0 buffer and eluted as previously described [12]. SAP purification was 
checked by silver stain on an SDS-PAGE gel and concentration was assessed by absorbance at 
280 nm.  Proteases were co-incubated with purified SAP to determine if proteases at 500 ng/ml 
cleaved SAP, which was run on 4-20% SDS gels and silver stained to assess proteolysis of SAP. 
SAP at 10 ug/ml was co-incubated with PBMC and proteases at the indicated concentration. 
 
Macrophage immunohistochemistry and secreted factors 
PBMC were cultured on 8-well tissue-culture treated slides (Millipore) as previously described 
[13] and exposed to trypsin, tryptase and thrombin at 12.5 ng/ml for five days. PBMC were 
allowed to dry by air before fixation in acetone for 10 minutes. The cells were stained for CCR7 
(mouse monoclonal clone 150503, R & D systems, Minneapolis, MN), CD163 (mouse 
monoclonal clone GH1/61, Biolegend, San Diego, CA), CD206 (mouse monoclonal clone 15-2, 
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Biolegend), and fibronectin (rabbit polyclonal, Sigma) as previously described [13]. Conditioned 
media from PBMC cultured in SFM with or without 12.5 ng/ml protease were analyzed for IL-10 
and IL-12 using a human IL-12 ELISA kit (Peprotech, Rocky Hill, NJ) and a human IL-10 
ELISA kit (Biolegend), following the manufacturer’s instructions.  
 
Gels and staining   
4-20% polyacrilamide gels (Bio-Rad)  were stained by using silver stain, and using a sequential 
stains-all stain followed by silver stain where indicated [14]. The concentration of the 
supplements was 500µg/ml. Proteins were mixed with 5µg/ml trypsin, and left overnight with 
tumbling at 37ºC.   
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CHAPTER III 
RESULTS 
 
Trypsin, thrombin, and tryptase potentiate fibrocyte differentiation  
Fibrocytes are involved in wound healing because they have the ability to secrete collagen and 
fibronectin. It has been previously shown that trypsin potentiates fibrocytes differentiation, 
because of this trypsin is commonly used topically in order to speed wound healing.  
Fibrocytes are fibroblast-like cells involved in the formation of scar tissue in healing wounds. 
The time required to form scar tissue in a wound is related to the amount of fibrocytes present 
[15]. Our results show that trypsin potentiates fibrocyte differentiation as expected (Figure 1A); 
we wanted to determine if other proteases had the same effect on fibrocyte differentiation as 
trypsin; consequently, we decided to test the effect of tryptase and thrombin on fibrocyte 
differentiation.  Human peripheral blood mononuclear cells (PBMC) were incubated for 5 days 
with either tryptase or thrombin in order to determine if fibrocyte differentiation was potentiated. 
After the incubation period the cells were stained, and the number of fibrocytes present under 
each condition was recorded. PBMC without protease served as a control for the experiment; we 
observed 388 to 1120 fibrocytes per 10
5
 PBMCs from a range of donors; these results agree with 
previous data [2]. The results indicate that tryptase and thrombin’s effects on fibrocyte 
differentiation are concentration dependent. Tryptase concentrations between 4 and 56 ng/ml and 
thrombin concentrations between 6 to 12.5 ng/ml increased the number of fibrocytes (Figure 1B-
D). Tryptase concentrations above 100 ng/ml and thrombin concentration about 400 ng/ml 
decreased the number of fibrocytes (Figures 1B and 1C); these results were consistent between 
different donors. After observing fibrocyte potentiation in the present of tryptase and thrombin, 
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collagen staining was performed by using flow cytometry. The results show that there is an 
increase in collagen staining in areas where fibrocyte potentiation occurs (Figure 2A-C). Neither 
tryptase nor thrombin had a significant effect on the number of adherent cells after the fixing and 
staining procedures (Figure 3). Consequently, both tryptase and thrombin potentiate fibrocyte 
differentiation, rather than increasing the cell adhesion of fibrocytes.   
 
Tryptase and thrombin potentiate fibrocyte differentiation in serum-containing media 
It has been previously shown that trypsin potentiates fibrocyte differentiation in media 
containing human serum [2]. We decided to test the ability of tryptase and thrombin to potentiate 
fibrocyte differentiation in media containing human serum. PBMC were incubated for 5 days in 
serum containing media in the presence of tryptase or thrombin. Fibrocyte differentiation is 
inhibited in the presence of serum without tryptase and thrombin (Figure 4); however, 
potentiation of fibrocyte differentiation occurred in serum containing media having 14 to 446 
ng/ml of tryptase and 28 to 112 ng/ml of thrombin. Tryptase and thrombin potentiate fibrocyte 
differentiation in the presence of human serum at particular concentrations.  
 
Trypsin potentiates fibrocyte differentiation in the absence of albumin 
Since trypsin, thrombin, and tryptase potentiate fibrocyte differentiation in the presence of 
albumin, then it is possible that fibrocyte differentiation is due to the proteases, or to an albumin 
fragment generated by proteolytic cleavage. To determine if albumin was necessary for the 
trypsin to potentiate fibrocyte differentiation, we tested the ability of trypsin potentiates fibrocyte 
differentiation in the absence of albumin, and in the presence of other protein supplements. Six 
different supplements were tested at 500ug/ml: human albumin, ovalbumin, casein, fish gelatin, 
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bovine skin gelatin, or skim milk powder. Trypsin potentiated fibrocyte differentiation in media 
supplemented with fish gelatin, and skim milk powder (Figure 5A and 5B); however, 
potentiation of fibrocyte differentiation was not observed in media supplemented with casein, 
ovalbumin, or bovine skin gelatin. SDS-PAGE gels indicated that the protease treatment of 
protein supplements caused the formation of digestion products in each case (Figures 10A-D). 
Therefore, albumin is not necessary for potentiation of fibrocyte differentiation to occur in the 
presence of trypsin. 
  
Trypsin, tryptase, and thrombin potentiate the differentiation of M2a macrophages 
Macrophages can differentiate into M1 subsets, which are associated with inflammation, and M2 
subsets, which are associated with tissue repair. Additionally, M2a macrophages are a subset of 
the M2 phenotype. M2a macrophages are associated with scar tissue formation. We wanted to 
determine if trypsin, thrombin, and tryptase had an effect on M2a macrophage differentiation. 
PBMC and proteases were co-incubated for five days, and then examined for macrophage 
markers. CCR7 is a used marker for M1 macrophage activation [16]. Trypsin, thrombin, nor 
tryptase increased CCR7 staining (Figures 6A and 7A). CD206 are makers of M2 macrophage 
differentiation used for M2 regulatory and M2a macrophage staining ([16],[17]). Each of the 
proteases increased CD206 staining, while tryptase and thrombin significantly increased CD163 
staining (Figures 6B, 6C, 7B and 7C). Fibronectin is a marker of M2a macrophage 
differentiation [18]. Our results show that every protease increased fibronectin stating (Figures 
6D and 7D). M1 and M2 macrophages differ in their secretion profiles; M1 macrophages secrete 
higher levels of cytokine IL-12 compared to M2 macrophages [19]. On the other hand, M2 
regulatory macrophages secrete increased levels of anti-inflammatory cytokine IL-10 [19]. 
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Trypsin and thrombin decrease M1 macrophage phenotype, for the extracellular accumulation of 
IL-12 was decreased in the presence of trypsin and thrombin, but not in the presence of tryptase 
(Figure 8A). On the other hand, tryptase and thrombin decrease the M2 regulatory phenotype, for 
the extracellular accumulation of IL-10 decreased in the presence of tryptase and thrombin 
(Figure 8B). Finally, our results indicate that trypsin, thrombin, and tryptase favor macrophage 
differentiation in PMBC populations towards the M2a phenotype.  
 
Tryptase and thrombin are able to compete with Serum Amyloid P (SAP) to potentiate 
fibrocyte differentiation 
Fibrocyte differentiation is potentiated in the presence of trypsin, tryptase, and thrombin; 
however, fibrocyte differentiation is inhibited in the presence of Serum Amyloid P (SAP). 
PMBC were co-incubating with trypsin, thrombin, or tryptase in the presence of 10 ug/ml of 
SAP, in order to determine if fibrocyte potentiation occurred in the presence of both protease and 
SAP. 10 ug/ml of SAP completely inhibited fibrocyte differentiation (Figure 9A-D); however, 
the effect of SAP on fibrocyte differentiation is modified in the presence of tryptase and 
thrombin (Figure 9B-D), but trypsin did not alter the effect of SAP on fibrocyte differentiation 
(Figure 9A and 9D). Also, tryptase and thrombin did not cleavage SAP, while trypsin did (Gel 
not shown).  
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CHAPTER IV 
DISCUSSION 
 
Fibrocytes contribute to the formation of scar tissue in both healing wounds and fibrosing 
diseases. Chronic wound healing and fibrosing diseases are a major medical issue in today’s 
society. More than 6.5 million people in the United States have a reduced quality of life due to 
non-healing chronic wounds. Also, the treatment chronic wounds cost more than $25 billion 
every year in the United States alone. On the other hand, fibrosing diseases account for 45% of 
deaths in United States [1]. Fibrocyte differentiation is essential to scar tissue formation in both 
chronic wound healing and fibrosing diseases.  
 
Our data indicates that tryptase and thrombin not only potentiate fibrocyte differentiation, but 
also collagen production. Fibrocyte potentiation occurred in the presence of protease and fish 
gelatin or milk powder, indicating that albumin is not necessary for fibrocyte differentiation to 
occur. Consequently, a protein additive in combination with protease is necessary for proteases 
to potentiate fibrocyte differentiation.  
 
Tryptase and thrombin effect on fibrocyte differentiation is concentration dependent. Tryptase 
and thrombin potentiated fibrocyte differentiation between 27 and 112 ng/ml; converting this 
concentration to a molar value shows that fibrocyte differentiation occurred between 30 to 120 
nM. Thrombin peak value was at a concentration of 30nM, which is the same concentration of 
thrombin in a wound [20].  
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Scar tissue formation is regulated in the human body by Serum Amyloid P (SAP). Fibrocyte 
differentiation is inhibited in the presence of SAP [12] , which is a pentameric protein prevalent 
in serum at a concentration of 30 µg/ml [21]. Our results and previous experiments indicate that 
SAP inhibits fibrocyte differentiation at a concentration of 10 µg/ml. The question then becomes:  
how does scar tissue formation begins in the presence of the high SAP concentrations found in 
serum? Our data indicates a possible explanation to the initiation of scar tissue formation in the 
body. Both tryptase and thrombin compete with SAP at 10 µg/ml allowing potentiation of 
fibrocyte differentiation to take place. Both tryptase and thrombin actively participate in wound 
healing; consequently, our data suggest that tryptase and thrombin allow scar tissue initiation to 
start at a wound site, due to their ability to compete with SAP.  
 
Macrophages exist in two populations. M1 macrophages participate in inflammation, and M2 
participate in remodeling.  M1 macrophages upregulate CCR7 and secrete more IL-12, while 
fibronectin is upregulated in M2a macrophages, which are a subset of M2 macrophages, and are 
involved in tissue remodeling and scar tissue formation [19]. Our data indicates that trypsin, 
tryptase and thrombin potentiate both fibrocyte differentiation, and M2a macrophage 
differentiation. Our results indicate that trypsin, tryptase, and thrombin allow scar tissue 
formation to take place not only because they potentiate fibrocyte differentiation, but also, 
because they increase the formation of M2a macrophages.  
 
Millions of people have a reduced quality of life due to the failure of chronic wounds to heal 
properly. Non-healing chronic wound disproportionately affect at-risk groups, including the 
elderly, obese and diabetics [2].  Non-healing chronic wounds respond poorly to conventional 
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treatments [2].There is a need to generate a treatment capable of treating non healing chronic 
wound. Fibrocytes are involved in scar tissue formation, and as the number of fibrocytes present 
at a wound site increase, the time required for the wound to heal decreases [15]. Our data shows 
that trypsin, tryptase, and thrombin potentiate fibrocyte differentiation, while tryptase and 
thrombin potentiate fibrocyte differentiation in the presence of SAP. Consequently, potentiation 
of fibrocyte differentiation by proteases at a wound site could be used as a therapeutic for non-
healing chronic wounds.  
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Figure 1. Trypsin, tryptase and thrombin potentiate fibrocyte differentiation. PBMC were 
cultured in serum free media in the presence of the indicated concentrations of (A) trypsin 
(n=13), (B) tryptase (n=10), or (C) thrombin (n=7) for 5 days. Fibrocyte counts were normalized 
for each donor to the no-protease control. The no-protease controls developed 187 ± 22 
fibrocytes per 10
5
 PBMC. Values in A through C are mean
 
±
 
SEM; the absence of error bars 
indicates that the error was smaller than the plot symbol. * indicates p < .05, ** indicates p < .01 
and *** indicates p < .001 compared to the no-protease control by a two tailed t-test. (D) Images 
of PBMC after incubating for 5 days of with no protease (control), 12.5 ng/ ml trypsin, 12.5 ng/ 
ml thrombin, or 55 ng/ ml tryptase. Bar is 40 µm 
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Figure 2. Tryptase and thrombin increase collagen secretion by PBMC. (A) Representative 
flow plots of no-protease control PBMC (black) and protease-treated PBMC (red) stained for 
collagen. PBMC were exposed to 12.5 ng/ml (B) tryptase or (C) thrombin for 5 days, 
resuspended, stained with anti-collagen and alexa-fluor secondary antibodies, and assayed for 
fluorescence by flow cytometry. Values are mean
 
±
 
SEM, n=5, * indicates p < .05 by a two tailed 
t-test.  
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Figure 3. Thrombin and tryptase do not significantly affect the total number of adhered 
PBMC. The same PBMC populations in Figure 1 were then counted for the total number of 
PBMC adhered to the plate following fixing and staining for (A) thrombin and (B) tryptase. 
Counts were normalized for each donor to the no-protease control. There were no significant 
differences in the numbers of adhered PBMC following fixing and staining. Peak fibrocyte 
concentrations are labeled on the graphs.  
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Figure 4. Thrombin and tryptase potentiate fibrocyte differentiation in the presence of 
human serum. PBMC were cultured in medium containing serum in the presence of the 
indicated concentrations of tryptase or thrombin for 5 days, and fibrocytes were counted as in 
Figure 1. Serum-containing media complete inhibited fibrocyte differentiation in the no-protease 
control. Values are mean
 
±
 
SEM, n = 4. * indicates p < .05, ** indicates p < .01 and *** indicates 
p < .001 compared to the no-protease control by a two tailed t-test. 
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Figure 5. Trypsin potentiates fibrocyte differentiation in the presence of fish gelatin or 
skim milk. PBMC were cultured in the presence of 500 µg/ml (A) fish gelatin (B) or powdered 
skim milk in the presence of the indicated concentrations of trypsin. After 5 days, fibrocytes 
were counted as in Figure 1. Values are mean
 
±
 
SEM, n=6. * indicates p < .05, ** indicates p < 
.01 compared to the no-protease control by a two tailed t-test. 
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Figure 6. Trypsin, tryptase, and thrombin favor macrophage differentiation towards an 
M2a phenotype. PBMC were cultured in serum-free media for 5 days on 8-well chamber slides 
in the presence of 12.5 ng/ml (A) trypsin, (B) thrombin, and (C) tryptase and no-protease 
controls. Control and protease treated PBMC were stained by alkaline-phosphatase 
immunohistochemistry for CCR7 (marker of M1 macrophages), CD163 and CD206 (enigmatic 
markers of M2 and M2a macrophages) and fibronectin (Unambiguous marker of M2a 
macrophages). Stains were developed for 7 minutes. Positively stained macrophages were 
counted and normalized to the total number of macrophages per donor.  
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Figure 7. Trypsin, tryptase and thrombin favor macrophage differentiation towards an 
M2a phenotype: representative images. PBMC were cultured as in Figure 9. Representative 
images of immunohistochemistry on PBMC after 5 days of no-protease, trypsin, thrombin, and 
tryptase using antibodies for (A) CCR7, (B) CD163, (C) CD206, and (D) fibronectin. Bar is 40 
µm.  
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Figure 8. Trypsin, tryptase and thrombin change PBMC secretion of IL-12 and IL-10 in 
PBMCconditioned media. PBMC were cultured as in Figure 9. (A) Conditioned media from 
PBMC after 5 days was analyzed by ELISA for IL-12 (marker of M1 macrophages) and IL-10 
(marker of M2reg macrophages). Values are mean
 
±
 
SEM, n=4. * indicates p < .05 compared to 
the no-protease control by a two tailed t-test.  
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Figure 9. Tryptase and thrombin compete with SAP to potentiate fibrocyte differentiation. 
PBMC mixed with Serum Amyloid P (SAP) at 10 µg/ml were incubated with the indicated 
concentrations of (A) trypsin, (B) tryptase, or (C) thrombin for 5 days. Fibrocytes were then 
counted as in Figure 1. Values are mean
 
±
 
SEM, n=4. * indicates p < .05 compared to proteases 
without SAP by t-test. (D) Images of PBMC after incubating for 5 days with 10 µg/ml SAP and 
either no protease (control), 12.5 ng/ ml trypsin, 3.5 ng/ ml thrombin, or 37.5 ng/ ml tryptase. Bar 
is 40 µm.  
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Figure 10. Trypsin cleavages media supplements  
(A-C) 4-20% polyacrilamide gels were stained with silver stain, and (D) using a sequential 
stains-all stain followed by silver stain. The concentration of the supplements was 500µg/ml. 
Proteins were mixed with 5µg/ml trypsin, and left overnight with tumbling at 37ºC.   
 
